Clinical trial
A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical…
NCT00445094 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00445094 |
|---|---|
| Title | A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) |
| Official title | A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infection, Pneumonia |
| Intervention type | Drug |
| Interventions | MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days, Comparator: amikacin / Duration of Treatment: 3 Days, Comparator: tazocin / Duration of Treatment: 3 Days, Comparator: vancomycin / Duration of Treatment: 3 Days |
| Enrollment | 120 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Mar 8, 2007 |
| Last update posted | Feb 17, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: